Philip Morris International Inc. (PM) · Oct 21, 2026 · Earnings

Philip Morris earnings beat as smoke-free growth offsets U.S. strain

Beat — Adjusted EPS $2.36 vs ~$2.34 consensus

Philip Morris earnings narrowly beat EPS expectations, with strong smoke-free growth and pricing offsetting weaker U.S. profitability and currency pressure.

Philip Morris is in the middle of its shift from cigarettes toward smoke-free products led by IQOS, ZYN and VEEV; smoke-free products were sold in 109 markets by June 30, 2026, while the company is also building a U.S.-centered business and wellness platform.

MetricQ3 2026Q3 2025 / expectationRead
Adjusted diluted EPS$2.36 (Schedule 2)~$2.34 published consensusNarrow beat
Net revenue$11.438B (Schedule 3)$10.845B; estimates clustered around $11.4B–$11.6BRoughly in line
Smoke-free revenue, organic growth$4.727B; +6.3% (Schedule 3)—Continued growth
U.S. smoke-free revenue, organic growth$846M; +25.3% (Schedule 3)—Strong
Adjusted operating companies income$5.112B; +10.5% organically (Schedule 9)$4.710B reported prior yearMargin/profit leverage
Operating cash flow$5.352B (Schedule 17)$4.462BStronger cash generation

The quarter cleared the cleanest market hurdle. Adjusted EPS of $2.36 modestly exceeded the published consensus around $2.34, while revenue growth was broadly consistent with the range of estimates available before the release. This is a narrow earnings beat rather than a broad upside surprise: the filing shows reported diluted EPS fell 4.9% to $2.12 because of currency and unusual items, while adjusted EPS rose 5.4% to $2.36 (Schedule 2).

The strategic transition is still working, but it is not yet evenly distributed. Smoke-free revenue grew organically 6.3% overall, with U.S. smoke-free revenue up 25.3% and U.S. wellness revenue up 30.5% (Schedule 3). International combustibles also grew 7.8% organically, showing PMI is still extracting substantial pricing from the legacy cigarette business while the newer portfolio expands. The result supports the existing smoke-free transition story rather than changing it; the direction was already well known, and the quarter mainly confirms continued execution.

The main weak spot remains U.S. profitability. U.S. adjusted operating companies income was only $171 million, up 1.5% organically in the quarter, and remained down 41.1% organically for the first nine months (Schedule 9). PMI's consolidated result was rescued by international pricing and mix: the quarterly variance analysis attributes $739 million of operating-income benefit to price against a $23 million volume/mix headwind and $64 million of cost pressure (Schedule 10). That makes the headline beat more dependent on pricing and international performance than on broad-based volume growth.

Cash generation and leverage improved despite the earnings noise. Operating cash flow rose to $5.352 billion from $4.462 billion, while net debt declined to $40.879 billion from $43.963 billion and net debt-to-adjusted-EBITDA improved to 2.17x from 2.53x (Schedules 16–17). That strengthens the financial base supporting PMI's smoke-free investment, although the filing does not provide a fresh full-year guidance change.

Bottom line: This is a modest earnings beat that reinforces PMI's smoke-free growth engine, especially in the U.S., while international pricing carries the quarter and U.S. profitability remains unfinished business. The event matters as confirmation of the strategy, not as a major change in the story.

Original filing on SEC EDGAR

More Philip Morris International Inc. news

Philip Morris earnings beat as smoke-free growth offsets U.S. strain | PM Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.